tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Apr 24;S1201-9712(22)00245-4.
doi: 10.1016/j.ijid.2022.04.047. Online ahead of print.
COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection
Efrén Murillo-Zamora[SUP] 1 [/SUP], Xóchitl Trujillo[SUP] 2 [/SUP], Miguel Huerta[SUP] 3 [/SUP], Mónica Ríos-Silva[SUP] 4 [/SUP], José Guzmán-Esquivel[SUP] 5 [/SUP], Verónica Benites-Godínez[SUP] 6 [/SUP], María Regina Ochoa-Castro[SUP] 7 [/SUP], José Alejandro Guzmán-Solórzano[SUP] 7 [/SUP], Oliver Mendoza-Cano[SUP] 8 [/SUP]
Affiliations
Abstract
Objectives: To compare, in a real-world scenario, the protective effect of vaccination and previous laboratory-confirmed symptomatic infection on the risk of coronavirus diseases 2019 (COVID-19) pneumonia.
Methods: A retrospective study was conducted and 46,998 adults with laboratory-positive COVID-19 were enrolled. Risk ratios (RR) and 95% confidence intervals (CI) were used to evaluate the effect of the evaluated exposures on the risk of pneumonia.
Results: In multiple analysis and after adjusting by reinfection status, vaccinated participants were at reduced risk of developing pneumonia (RR = 0.974, 95% CI 0.965-0.983). The association of having had a previous infection was not significant (RR = 1.001, 95% CI 0.969-1.034).
Conclusions: Our results suggest, and if later replicated, that COVID-19 vaccines provide better protection against pneumonia than previous symptomatic infections. Therefore, offering vaccination to all eligible subjects despite of they have had COVID-19 might be relevant to reducing the pandemic-related burden.
Keywords: COVID-19; COVID-19 Vaccines; Pneumonia; SARS-CoV-2.
. 2022 Apr 24;S1201-9712(22)00245-4.
doi: 10.1016/j.ijid.2022.04.047. Online ahead of print.
COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection
Efrén Murillo-Zamora[SUP] 1 [/SUP], Xóchitl Trujillo[SUP] 2 [/SUP], Miguel Huerta[SUP] 3 [/SUP], Mónica Ríos-Silva[SUP] 4 [/SUP], José Guzmán-Esquivel[SUP] 5 [/SUP], Verónica Benites-Godínez[SUP] 6 [/SUP], María Regina Ochoa-Castro[SUP] 7 [/SUP], José Alejandro Guzmán-Solórzano[SUP] 7 [/SUP], Oliver Mendoza-Cano[SUP] 8 [/SUP]
Affiliations
- PMID: 35477053
- DOI: 10.1016/j.ijid.2022.04.047
Abstract
Objectives: To compare, in a real-world scenario, the protective effect of vaccination and previous laboratory-confirmed symptomatic infection on the risk of coronavirus diseases 2019 (COVID-19) pneumonia.
Methods: A retrospective study was conducted and 46,998 adults with laboratory-positive COVID-19 were enrolled. Risk ratios (RR) and 95% confidence intervals (CI) were used to evaluate the effect of the evaluated exposures on the risk of pneumonia.
Results: In multiple analysis and after adjusting by reinfection status, vaccinated participants were at reduced risk of developing pneumonia (RR = 0.974, 95% CI 0.965-0.983). The association of having had a previous infection was not significant (RR = 1.001, 95% CI 0.969-1.034).
Conclusions: Our results suggest, and if later replicated, that COVID-19 vaccines provide better protection against pneumonia than previous symptomatic infections. Therefore, offering vaccination to all eligible subjects despite of they have had COVID-19 might be relevant to reducing the pandemic-related burden.
Keywords: COVID-19; COVID-19 Vaccines; Pneumonia; SARS-CoV-2.
